Tandem Diabetes Care has appointed Jean-Claude Kyrillos as Chief Operating Officer, effective Thursday. Kyrillos will lead efforts to expand the company’s global operations and drive profitable growth. His previous roles include positions at Envista, Qualcomm’s healthcare unit, Becton Dickinson, and Resmed.
Tandem CEO John Sheridan highlighted Kyrillos’s extensive healthcare experience and balanced skill set, which includes technical, operational, and leadership expertise from both large and small medical technology companies.
Kyrillos’s appointment fills the vacancy left by David Berger, who stepped down as COO at the end of 2023 after a decade with Tandem. Berger led the company’s clinical, quality, and regulatory functions and will remain involved through a transition and consulting agreement until June 30.
This leadership change follows Tandem’s recent update on its agreements with Dexcom, initially made in 2020. The revised agreements extend the integration of Tandem’s Sigi insulin pump with Dexcom’s G7 continuous glucose monitoring device for an additional five years.
